Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Citations Over TimeTop 1% of 2009 papers
Abstract
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Related Papers
- → Correlation between Triazole Treatment History and Susceptibility in Clinically Isolated Aspergillus fumigatus(2012)98 cited
- → Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia(2023)3 cited
- → Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study(2018)24 cited
- → Success of posaconazole therapy in a heart transplanted patient withAlternaria infectoriacutaneous infection(2012)11 cited
- → Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis(2008)16 cited